JW Life Science

JW Life Science EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of JW Life Science (234080.KS) as of Oct 17, 2026 is 33.24 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 36.35 B KRW — a change of -8.54% (lower).

EBITDA

33.24 BKRW

YoY

-8.54%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of JW Life Science is 2025 33.24 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of JW Life Science was 2024 36.35 B KRW. It decreases by -8.54% lower compared to the previous year.

The JW Life Science EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2017
24.22 B KRW
Jan 1, 2018
24.06 B KRW
Jan 1, 2019
30.79 B KRW
Jan 1, 2020
40.70 B KRW
Jan 1, 2021
29.72 B KRW
Jan 1, 2022
28.70 B KRW
Jan 1, 2023
36.35 B KRW
Jan 1, 2025
33.24 B KRW
The JW Life Science EBITDA history
YEAREBITDAYoY
33.24 BKRW-8.54%
36.35 BKRW+26.63%
28.70 BKRW-3.40%
29.72 BKRW-26.99%
40.70 BKRW+32.20%
30.79 BKRW+27.97%
24.06 BKRW-0.67%
24.22 BKRW+9.94%
22.03 BKRW+15.83%
19.02 BKRW+26.87%
14.99 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

JW Life Science Stock analysis

What does JW Life Science do? JW Life Science Corp is a South Korean pharmaceutical company headquartered in Dangjin. The company manufactures intravenous fluids including basic IV fluids with water, electrolytes, and glucose; nutrient infusion solutions containing amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions for specific medical cases. It also produces total parenteral nutrition (TPN) products. The company went public on October 27, 2016, with its stock listed on the Korea Exchange under ticker 234080.KS. Its ISIN is KR723080000. The company's website is https://www.jw-lifescience.co.kr/ JW Life Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JW Life Science stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of JW Life Science is 33.24 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of JW Life Science changed from 36.35 B KRW to 33.24 B KRW, representing a -8.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) JW Life Science since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JW Life Science historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — JW Life Science

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — JW Life Science